These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11307045)

  • 21. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease.
    Goberman AM; Blomgren M
    J Voice; 2008 Mar; 22(2):178-91. PubMed ID: 16950600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
    Azevedo LL; Souza IS; Oliveira PM; Cardoso F
    Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on parkinsonian voice using perturbation, nonlinear dynamic, and perceptual analysis.
    Zhou XP; Lee VS; Wang EQ; Jiang JJ
    Folia Phoniatr Logop; 2009; 61(4):189-99. PubMed ID: 19590218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M; Santens P; Van Borsel J
    J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading.
    Rabey JM; Klein C; Molochnikov A; Van Hilten B; Krauss P; Bonuccelli U
    Clin Neuropharmacol; 2002; 25(2):83-8. PubMed ID: 11981234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?
    Cantiniaux S; Vaugoyeau M; Robert D; Horrelou-Pitek C; Mancini J; Witjas T; Azulay JP
    J Neurol Neurosurg Psychiatry; 2010 Feb; 81(2):177-84. PubMed ID: 19793764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
    Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.
    Skodda S; Grönheit W; Schlegel U
    J Voice; 2011 Jul; 25(4):e199-205. PubMed ID: 21051196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acoustic comparison of vowel sounds among adult females.
    Franca MC
    J Voice; 2012 Sep; 26(5):671.e9-17. PubMed ID: 22285451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Voice target time in Parkinson's disease: A preliminary report.
    Jiang J; Lin E; Sheynin B; Hanson DG
    Otolaryngol Head Neck Surg; 1999 Jul; 121(1):87-91. PubMed ID: 10388885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease.
    Sriranjini SJ; Ganesan M; Datta K; Pal PK; Sathyaprabha TN
    Neurol India; 2011; 59(5):659-63. PubMed ID: 22019646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic influences on the P300 abnormality in Parkinson's disease.
    Sohn YH; Kim GW; Huh K; Kim JS
    J Neurol Sci; 1998 Jun; 158(1):83-7. PubMed ID: 9667783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.